COVID-19 / Coronavirus

Grand Pharma Announces Successful Clinical Progress of its Oral 3CL Protease Inhibitor GS221 Against COVID-19

2022-12-30 13:23 2967

* GS221 has conducted 3 clinical trials. Current results of clinical trials show favorable safety and tolerance in the subjects. After administration, the patients showed trends of improvement of clinical symptoms, shortening time for negative nucleic acid test, and rapid decline of viral load;...

China enters new stage in COVID-19 response

2022-12-29 22:00 2289

BEIJING, Dec. 29, 2022 /PRNewswire/ -- A news report by China.org.cn on China's COVID-19 response:   Changes are taking place to China's COVID-19 response. Now, efforts are being accelerated across the country to fully reopen the economy, and people are generally no longer requ...

CGTN: Vitality under COVID-19: China's smart ports aid increased throughput

2022-12-29 11:55 6942

BEIJING, Dec. 29, 2022 /PRNewswire/ -- China's Qingdao Port, a subsidiary of Shandong Port Group and the second-largest foreign trade port in eastChina's Shandong Province, has seen an increase in anchorage rotations of very large container ships, according to China Media Group. The port has han...

Global Times: Three years' hard effort to fight COVID-19 'worthwhile'

2022-12-28 21:38 1993

BEIJING, Dec. 28, 2022 /PRNewswire/ -- After three years' hard effort to keep the COVID-19 at bay,China has optimized its virus responses recently. The Global Times has talked with front line medical workers, grass-roots community workers and others about their experience in the three-year battle...

China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask

2022-12-28 21:00 2276

HAIKOU, China, Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the launch of N95 medical protect...

Takeda Healthcare Philippines Inc Honored the Inspirational Award at the Asia Pacific Enterprise Awards 2022 Regional Edition

2022-12-28 15:30 2287

SINGAPORE, Dec. 28, 2022 /PRNewswire/ -- Enterprise Asia, the organizer of the Asia Pacific Enterprise Awards (APEA) 2022 Regional Edition, is pleased to recognize 25 exemplary business leaders and enterprises acrossAsia which excelled and showcased unparalleled resilience and growth despite theC...

SAVEWO introduces the only Hong Kong-made respirator obtaining top EU and China certifications, enters medical market with increased investment and production capacity

2022-12-28 11:00 2633

HONG KONG, Dec. 28, 2022 /PRNewswire/ -- While the COVID-19 pandemic stabilises inHong Kong and many resume normal life, Hong Kong-based mask developer and manufacturer SAVEWO plans to increase investment and production capacity, pivoting from masks for the mass to the professional medical grade ...

Everest Medicines Commences Operations at its mRNA Vaccine Manufacturing Facility, Accelerating Evolution to a Fully-Integrated Biopharma

2022-12-28 08:00 2897

--Everest owns complete pharmaceutical and vaccine value chain from discovery, clinical development, manufacturing and commercialization-- --Localizes company's mRNA vaccine production, and helps meet urgent China and global demand for innovative vaccines and medicines-- SHANGHAI, Dec. 28, 2022 ...

CGTN: Vitality under COVID-19: China gears up for medical supplies

2022-12-28 00:13 6694

BEIJING, Dec. 28, 2022 /PRNewswire/ -- China has made efforts to ensure the medical supplies needed for COVID-19 prevention and control after it loosened its epidemic measures in early December, which was followed by an increase in infections and surging demand for medicines. The country's Natio...

Brii Biosciences Provides Update on Strategic Clinical Development Progress

2022-12-27 20:00 2794

Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination studies expected in the first half of 2023 Initiation of Phase 2 postpartum depression (PPD) study planned for early 2023 to advance potential first-of-its-kind treatment U.S. FDA lifted clinical hol...

China to downgrade COVID-19 management to Class B

2022-12-27 18:06 2270

BEIJING, Dec. 27, 2022 /PRNewswire/ -- A report from People's Daily: China will downgrade management of COVID-19 to Class B and cancel quarantine requirements on inbound travelers fromJan. 8, 2023, China's top health authority announced recently. In a statement released late Monday, the National...

Hetero's 'Nirmacom' is world's first generic version of COVID-19 oral drug 'PAXLOVID' to receive WHO Prequalification

2022-12-27 10:00 3394

* Hetero's 'Nirmacom' (Nirmatrelvir), a generic version of Pfizer's COVID-19 oral antiviral drug 'PAXLOVID' is co-packaged with ritonavir tablets * With the launch of Nirmacom, Hetero aims to expand access of the ground-breaking antiviral in 95 LMICs including India HYDERABAD, India, Dec. 27, ...

China actively optimizes COVID-19 response measures to better prepare for challenges

2022-12-26 14:32 3184

BEIJING, Dec. 26, 2022 /PRNewswire/ -- As multiple regions in China have seen surging COVID-19 infections, local governments are taking swift and precise measures to prevent severe cases, protect people's health, and build a barrier against the epidemic. These measures include providing timely m...

Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company's Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

2022-12-26 11:33 4053

TAIZHOU, China, Dec. 26, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant two-component COVID-19...

AAHRPP Accredits Three More Research Organizations, Including First Hospital in Japan

2022-12-23 20:25 2859

Twelve earn accreditation in 2022, returning to pre-COVID-19 levels WASHINGTON, Dec. 23, 2022 /PRNewswire/ -- The Association for the Accreditation of Human Research Protection Programs has accredited three more research organizations, including the first hospital inJapan, the flagship universit...

Fosun International Granted Three Awards from Global Banking and Finance Review in the United Kingdom

2022-12-23 10:52 3721

HONG KONG, Dec. 23, 2022 /PRNewswire/ -- On 23 December 2022, Fosun International was notified byGlobal Banking and Finance Review, a famous financial magazine in theUnited Kingdom, that Fosun International was granted three awards, namely "Brand of the Year Awards - Holding Group Brand of the Y...

Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis

2022-12-22 08:00 3356

SHANGHAI, Dec. 22, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received acceptance from the U.S. Food and Drug Administration (FDA) for review a New Drug Application (NDA) for etrasimod for individuals living with ...

CGTN: 'New Approaches': How China stepped up its COVID-19 treatments

2022-12-21 18:51 2201

BEIJING, Dec. 21, 2022 /PRNewswire/ -- China has been racing against the clock in developing COVID-19 drugs while promoting vaccination – one for saving lives and the other for providing broad protection. While the stringent COVID-19 containment measures of the past three years helpedChina evade...

CPIC: "CPIC Elite Club" Creates High Quality Services Escorts for Healthy Living

2022-12-21 15:26 3673

HONG KONG, Dec. 21, 2022 /PRNewswire/ -- The insurance industry is a "stabiliser" for social development and a "booster" for economic growth. In recent years,China's insurance industry has been growing rapidly. Since 2017 in whichChina's premium income exceeded that of Japan, China's premium inco...

Ascletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned

2022-12-21 08:00 2336

HANGZHOU and SHAOXING, China, Dec. 21, 2022 /PRNewswire/ -- The enrollment of the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 developed in house by Gannex Pharma Co., Ltd., a wholly owned subsidiary of Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), for tr...

1 ... 19202122232425 ... 226